Globus Medical, Inc. filed a Form 8-K with the SEC on November 5, 2026, disclosing a $500.0 million increase to its existing share repurchase program and furnishing a press release covering its sales and operating results for the three and nine month period ended September 30, 2026.

Key Highlights

  • Repurchase program expanded: The Board of Directors authorized an additional $500.0 million in Class A common stock repurchases on November 2, 2026.
  • Total availability: Approximately $611.0 million remained available for future repurchases under the program as of November 2, 2026.
  • No time limit: The repurchase program has no time limit and may be suspended or discontinued at any time, according to the filing.
  • Repurchase methods: Repurchases may be made through privately negotiated transactions or open market transactions, including pursuant to a trading plan under Rule 10b5-1 and/or Rule 10b-18.
  • Quarterly results furnished: A press release reporting sales and operating results for the three and nine month period ended September 30, 2026, was furnished as Exhibit 99.1.
  • Signed by CFO: The filing was signed by Kyle R. Kline, Chief Financial Officer and Senior Vice President, on November 5, 2026.

Globus Medical Discloses $500 Million Buyback Increase and Q3 2026 Results

Globus Medical, Inc. (NYSE:GMED), headquartered in Audubon, Pennsylvania, filed a current report on November 5, 2026, covering two separate disclosures. Under Item 8.01, the company reported that its Board of Directors authorized a $500.0 million increase to its existing share repurchase program on November 2, 2026, described in the filing as the "Repurchase Program Increase Date." Following that authorization, approximately $611.0 million remained available for future repurchases under the program as of that date.

According to the filing, the timing and actual number of shares repurchased will be determined by management at its discretion and will depend on factors including "market price of the shares, general business and market conditions, applicable legal requirements, and alternative investment opportunities." The program carries no expiration date and may be suspended for periods or discontinued at any time. Repurchases may be executed through open market transactions or privately negotiated transactions, including through a plan consistent with Rule 10b5-1 and/or Rule 10b-18 under the Securities Act.

Under Item 2.02, the company furnished a press release dated November 5, 2026, as Exhibit 99.1, reporting its sales and operating results for the three and nine month period ended September 30, 2026. The filing noted that the information in Item 2.02 and its attached exhibit "shall be deemed to be 'furnished' and shall not be deemed to be 'filed'" with the SEC for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

What Was Disclosed

Globus Medical disclosed a $500.0 million addition to its share repurchase program, leaving approximately $611.0 million available as of November 2, 2026, and furnished a press release covering its results for the three and nine month period ended September 30, 2026.